Reuters logo
BRIEF-Clovis Oncology says topline data from Ariel3 trial of rucaparib achieved primary endpoint
2017年6月19日 / 早上7点52分 / 3 个月前

BRIEF-Clovis Oncology says topline data from Ariel3 trial of rucaparib achieved primary endpoint

June 19 (Reuters) - Clovis Oncology Inc:

* Clovis Oncology - announced topline data from the confirmatory phase 3 ariel3 trial of rucaparib

* Clovis Oncology - ariel3 trial achieved primary endpoint of improved progression-free survival by investigator review in each of 3 populations studied

* Clovis Oncology - PFS was improved in rucaparib group compared with placebo by blinded independent central review (BICR) a key secondary endpoint

* Clovis Oncology - company plans to submit a supplemental NDA within the next four months Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below